Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Blackham A and Griffiths RJ | The effect of FK506 and cyclosporin A on antigen-induced arthritis. | 1991 | Clin. Exp. Immunol. | pmid:1718639 |
Carobbi A et al. | Effect of splenectomy in combination with FK 506 and 15-deoxyspergualin on cardiac xenograft survival. | 1991 | Transplant. Proc. | pmid:1703704 |
McMichael J et al. | Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1721275 |
Zeevi A et al. | In vitro assessment of FK 506 immunosuppressive activity in transplant patients. | 1991 | Transplant. Proc. | pmid:1721307 |
Shaw BW et al. | FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. | 1991 | Transplant. Proc. | pmid:1721338 |
McDiarmid SV et al. | FK 506 rescue therapy in liver transplantation: outcome and complications. | 1991 | Transplant. Proc. | pmid:1721339 |
Wijnen RM et al. | Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. | 1991 | Transplant. Proc. | pmid:1721371 |
Lagodziński Z et al. | Effect of FK 506 on B-cell responses. | 1991 | Transplant. Proc. | pmid:1703359 |
Morrisett JD et al. | Effect of FK 506 and cyclosporine on plasma cholesterol levels in rabbits. | 1991 | Transplant. Proc. | pmid:1721402 |
Wiederrecht G et al. | FKB1 encodes a nonessential FK 506-binding protein in Saccharomyces cerevisiae and contains regions suggesting homology to the cyclophilins. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1704127 |
Wu GD et al. | FK 506 inhibits the development of transplant arteriosclerosis. | 1991 | Transplant. Proc. | pmid:1721433 |
Kobayashi N et al. | Effect of FK 506 on abdominal organ cluster transplantation in pigs. | 1991 | Transplant. Proc. | pmid:1721434 |
Shiraki K et al. | Effect of FK-506 on replication of human cytomegalovirus in vitro. | 1991 | J. Antibiot. | pmid:1712008 |
Matsuura T et al. | [Experimental studies on the mode of action of cyclosporine and FK506 assessed by proliferation response of human cloned T lymphocytes]. | 1991 | Hinyokika Kiyo | pmid:1721767 |
Morris RE | Rapamycin: FK506's fraternal twin or distant cousin? | 1991 | Immunol. Today | pmid:1715165 |
Baumann G et al. | Cyclosporin A and FK-506 both affect DNA binding of regulatory nuclear proteins to the human interleukin-2 promoter. | 1991 | New Biol. | pmid:1715185 |
Jiang H et al. | Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. | 1991 | Transplant. Proc. | pmid:1703702 |
Gailliot FP et al. | Fluidized bed adsorption for whole broth extraction. | 1990 Sep-Oct | Biotechnol. Prog. | pmid:1366874 |
Naouri A and Tissot E | [Indications for liver transplantation in adults]. | 1990 Jun-Jul | J Chir (Paris) | pmid:1698800 |
MacLeod AM and Thomson AW | [FK-506. A new immunosuppressive drug]. | 1990 Jul-Sep | Medicina (Firenze) | pmid:1706817 |
Wasik M et al. | Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. | 1990 Jul-Aug | Immunopharmacology | pmid:1699911 |
Li PK et al. | The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. | 1990 | Adverse Drug React Acute Poisoning Rev | pmid:1703724 |
Mieles L et al. | Oral glucose tolerance test in liver recipients treated with FK 506. | 1990 | Transplant. Proc. | pmid:1689894 |
Alessiani M et al. | Infections with FK 506 immunosuppression: preliminary results with primary therapy. | 1990 | Transplant. Proc. | pmid:1689895 |
Staschak S et al. | A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent. | 1990 | Transplant. Proc. | pmid:1689896 |
Second International Workshop on FK 506. A potential breakthrough in immunosuppression: clinical implications. October 31, 1989, Barcelona, Spain. Proceedings. | 1990 | Transplant. Proc. | pmid:1689897 | |
Cadoff EM et al. | Assay of FK 506 in plasma. | 1990 | Transplant. Proc. | pmid:1689898 |
Venkataramanan R et al. | Pharmacokinetics of FK 506: preclinical and clinical studies. | 1990 | Transplant. Proc. | pmid:1689899 |
Jain AB et al. | Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. | 1990 | Transplant. Proc. | pmid:1689900 |
Fung JJ et al. | Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. | 1990 | Transplant. Proc. | pmid:1689901 |
Zeevi A et al. | Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression. | 1990 | Transplant. Proc. | pmid:1689902 |
Imventarza O et al. | Renal transplantation in baboons under FK 506. | 1990 | Transplant. Proc. | pmid:1689903 |
Thomas FT et al. | Comparative efficacy of immunosuppressive drugs in xenografting. | 1990 | Transplant. Proc. | pmid:1693452 |
Harrison RK and Stein RL | Substrate specificities of the peptidyl prolyl cis-trans isomerase activities of cyclophilin and FK-506 binding protein: evidence for the existence of a family of distinct enzymes. | 1990 | Biochemistry | pmid:1693856 |
Starzl TE et al. | Kidney transplantation under FK 506. | 1990 | JAMA | pmid:1693970 |
Bierer BE et al. | Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. | 1990 | Transplantation | pmid:1694317 |
Eiras G et al. | Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. | 1990 | Transplantation | pmid:1694318 |
Tze WJ et al. | In vitro effects of FK-506 on human and rat islets. | 1990 | Transplantation | pmid:1694319 |
Maki N et al. | Complementary DNA encoding the human T-cell FK506-binding protein, a peptidylprolyl cis-trans isomerase distinct from cyclophilin. | 1990 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1695378 |
Doe SE et al. | Early effects of the immunosuppressive drug FK-506 on signal transduction in lymphocytes. | 1990 | Biochem. Soc. Trans. | pmid:1695581 |
Murase N et al. | Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. | 1990 | Transplantation | pmid:1696405 |
Propper DJ et al. | FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. | 1990 | Transplantation | pmid:1696409 |
Arita C et al. | Inhibition by FK506 of established lesions of collagen-induced arthritis in rats. | 1990 | Clin. Exp. Immunol. | pmid:1702374 |
Woo J et al. | Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion. | 1990 | Clin. Exp. Immunol. | pmid:1702375 |
Mattila PS et al. | The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. | 1990 | EMBO J. | pmid:1702384 |
Kawashima H et al. | Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. | 1990 | Invest. Ophthalmol. Vis. Sci. | pmid:1702408 |
Wilkinson PC and Watson EA | FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. | 1990 | Immunology | pmid:1702750 |
Metcalfe S and Milner J | Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. | 1990 | Immunol. Lett. | pmid:1702753 |
Takada K et al. | Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. | 1990 | J. Chromatogr. | pmid:1703552 |
Akutsu I et al. | [Inhibitory effect of FK-506 on the development of late asthmatic response and on the increased bronchial responsiveness]. | 1990 | Arerugi | pmid:1705791 |